1 Min Read
Sept 20 (Reuters) - PhaseRx Inc:
* PhaseRx receives Orphan Drug Designation from FDA for PRX-ASL for the treatment of Argininosuccinate Lyase Deficiency Source text for Eikon: Further company coverage:
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2018 Reuters. All Rights Reserved.